EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Efficacy of apremilast in hyperkeratotic hand and foot dermatitis: results from a randomized observer‐blinded comparative study

Kriti Bhat iD, Suman Patra iD, Abhishek Bhardwaj, Saurabh Singh iD, Anil Budania, Anupama Bains, Suman Saurabh

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17185 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Kriti Bhat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India. Hauptthemen laut MEDLINE: Thalidomide, Severity of Illness Index, Hand Dermatoses, Foot Dermatoses. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperkeratotic hand and foot dermatitis significantly affects quality of life. Some patients respond suboptimally to topical corticosteroids and have multiple recurrences.

Objective

Our aim was to compare the efficacy and safety profile of apremilast and topical corticosteroid versus corticosteroid alone in hyperkeratotic hand and foot dermatitis.

Methods

This randomized controlled study involved 77 patients treated for 3 months. Group A (39 patients) received mometasone furoate 0.1% cream with oral apremilast 30 mg twice daily, and Group B (38 patients) received mometasone alone. They were assessed monthly using the Hand Eczema Clinical Severity Index (HECSI) and Visual Analogue Scale (VAS) scores for pruritus. Investigator Global Assessment (IGA) and Quality of Life in Hand Eczema Questionnaire (QOLHEQ) were conducted at the end of 3 months.

Results

The HECSI, VAS score, and QOLHEQ showed a significant decrease in both groups from baseline to the third month. Intergroup comparisons of HECSI failed to reach the significance level. When compared, patients receiving apremilast had significantly better improvement in the third month according to the Patient Global Assessment (PGA) and Investigator Global Assessment (IGA). They also had a smaller number of flares.

Conclusion

Adding apremilast to topical corticosteroid leads to better patient and physician‐perceived improvement and reduces the number of flares in hyperkeratotic hand eczema.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideSeverity of Illness IndexHand DermatosesFoot DermatosesQuality of LifeMometasone FuroateHumansMaleFemaleAdultMiddle AgedTreatment OutcomeDrug Therapy, CombinationSingle-Blind MethodAnti-Inflammatory Agents, Non-SteroidalPruritusAdministration, OralKeratosisAdministration, CutaneousSkin CreamYoung Adult

Stichwörter der Autor:innen

apremilasthand dermatitishyperkeratoticmometasonerelapse

Substanzen

apremilastThalidomideMometasone FuroateAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India.
  • Department of Community Medicine And Family Medicine, All India Institute of Medical Sciences Jodhpur, Jodhpur, India.

ORCID-Profile: Kriti Bhat, Suman Patra, Saurabh Singh

Zitieren

APA

Bhat, K., Patra, S., Bhardwaj, A., Singh, S., Budania, A., Bains, A., & Saurabh, S. (2024). Efficacy of apremilast in hyperkeratotic hand and foot dermatitis: results from a randomized observer‐blinded comparative study. International Journal of Dermatology. https://doi.org/10.1111/ijd.17185

Vancouver

Bhat K, Patra S, Bhardwaj A, Singh S, Budania A, Bains A, et al. Efficacy of apremilast in hyperkeratotic hand and foot dermatitis: results from a randomized observer‐blinded comparative study. International Journal of Dermatology. 2024. doi:10.1111/ijd.17185

BibTeX
@article{Bhat2024,
  author = {Bhat, Kriti and Patra, Suman and Bhardwaj, Abhishek and Singh, Saurabh and Budania, Anil and Bains, Anupama and Saurabh, Suman},
  title = {Efficacy of apremilast in hyperkeratotic hand and foot dermatitis: results from a randomized observer‐blinded comparative study},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17185}
}
Kostenlos starten →